Technical Analysis for MLNTQ - Melinta Therapeutics Inc

Grade Last Price % Change Price Change
grade D 0.1749 -7.95% -0.0151
MLNTQ closed down 7.95 percent on Thursday, February 20, 2020, on 24 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical MLNTQ trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Hot IPO Pullback Bullish Swing Setup -7.95%
Lower Bollinger Band Walk Weakness -7.95%
Inside Day Range Contraction -7.95%
Wide Bands Range Expansion -7.95%
Oversold Stochastic Weakness -7.95%
Stochastic Buy Signal Bullish -0.06%
Hot IPO Pullback Bullish Swing Setup -0.06%
New 52 Week Low Weakness -0.06%
Older signals for MLNTQ ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is based in Morristown, New Jersey. On December 27, 2019, Melinta Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Medicine Health RTT Pharmaceutical Chemical Compounds U.S. Bankruptcy Court Infection U.S. Bankruptcy Court For The District Of Delaware Antibiotic Anti Acne Preparations Anti Infectives Tetracycline Antibiotics Delafloxacin Gram Negative Infections Bacterial Infectious Diseases Baxdela Lipoglycopeptide Medical Research Council Melinta Therapeutics Skin Structure Infections Tetracycline Treatment Of Bacterial Infectious Diseases Yale University

Is MLNTQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.5
52 Week Low 0.1504
Average Volume 134,482
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.3362
10-Day Moving Average 0.2479
Average True Range 0.0487
ADX 0.0
+DI 7.1533
-DI 31.0370
Chandelier Exit (Long, 3 ATRs ) 0.3539
Chandelier Exit (Short, 3 ATRs ) 0.2965
Upper Bollinger Band 0.5394
Lower Bollinger Band 0.1330
Percent B (%b) 0.1
BandWidth 120.8804
MACD Line -0.0934
MACD Signal Line -0.0602
MACD Histogram -0.0332
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.2240
Resistance 3 (R3) 0.2269 0.2134 0.2158
Resistance 2 (R2) 0.2134 0.2009 0.2120 0.2130
Resistance 1 (R1) 0.1942 0.1932 0.2038 0.1913 0.2103
Pivot Point 0.1807 0.1807 0.1856 0.1793 0.1807
Support 1 (S1) 0.1615 0.1682 0.1711 0.1586 0.1395
Support 2 (S2) 0.1480 0.1605 0.1466 0.1368
Support 3 (S3) 0.1288 0.1480 0.1340
Support 4 (S4) 0.1259